Should You Already Consider Disposing Your Zai Lab (ZLAB) Shares?

ClearBridge Investments, an investment management firm, published its “International Growth ACWI ex-U.S. Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. During the fourth quarter, the ClearBridge International Growth ACWI ex-U.S. Strategy outperformed its MSCI ACWI Ex-U.S. benchmark. The Strategy delivered gains across seven of the 10 sectors in which it was invested (out of 11 total), with the consumer staples, industrials, health care, and materials sectors the primary contributors. The financials, communication services, and consumer discretionary sectors were detractors. Spare some time to check the fund’s top 5 holdings to have a clue about their top bets for 2022.

ClearBridge Investments International Growth ACWI ex-U.S. Strategy, in its Q4 2021 investor letter, mentioned Zai Lab Limited (NASDAQ:ZLAB) and discussed its stance on the firm. Founded in (2013), Zai Lab Limited (NASDAQ:ZLAB) is a Cayman Islands-based biopharmaceutical company with a $4.7 billion market capitalization and is currently spearheaded by its CEO, Samantha Du. Zai Lab Limited (NASDAQ:ZLAB) delivered a -20.95% return since the beginning of the year, while its 12-month returns are down by -61.09%. The stock closed at $49.68 per share on April 04, 2022.

Here is what ClearBridge Investments International Growth ACWI ex-U.S. Strategy has to say about Zai Lab Limited (NASDAQ:ZLAB) in its Q4 2021 investor letter:

“Economies in Asia, meanwhile, are taking the opposite approach on stimulus, with China lowering its reserve requirement ratio for banks to support flagging growth in the world’s second-largest economy. Japan’s new government passed a large stimulus bill after its economy contracted in the third quarter. Despite these actions, sentiment remains decidedly negative in these regions. Our underweight to Japan proved beneficial during the quarter while our single holding in China – biotechnology company Zai Lab – sold off sharply mostly due to generally weak sentiment around Chinese health care stocks.”

Our calculations show that Zai Lab Limited (NASDAQ:ZLAB) failed to obtain a mark on our list of the 30 Most Popular Stocks Among Hedge Funds. Zai Lab Limited (NASDAQ:ZLAB) was in 32 hedge fund portfolios at the end of the fourth quarter of 2021, compared to 36 funds in the previous quarter. Zai Lab Limited (NASDAQ:ZLAB) delivered a -16.64% return in the past 3 months. 

In January 2022, we also shared another hedge fund’s views on Zai Lab Limited (NASDAQ:ZLAB) in another article. You can find other letters from hedge funds and prominent investors on our hedge fund investor letters 2021 Q4 page.

Disclosure: None. This article is originally published at Insider Monkey.